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Xenon is a medical gas capable of establishing neuroprotection, inducing anesthesia as well as serving in modern
laser technology and nuclear medicine as a contrast agent. In spite of its high cost, its lack of side effects, safe
cardiovascular and organoprotective profile and effective neuroprotective role after hypoxic-ischemic injury (HI)
favor its applications in clinics. Xenon performs its anesthetic and neuroprotective functions through binding to
glycine site of glutamatergic N-methyl-D-aspartate (NMDA) receptor competitively and blocking it. This blockage
inhibits the overstimulation of NMDA receptors, thus preventing their following downstream calcium accumulating
cascades. Xenon is also used in combination therapies together with hypothermia or sevoflurane. The
neuroprotective effects of xenon and hypothermia cooperate synergistically whether they are applied
synchronously or asynchronously. Distinguishing properties of Xenon promise for innovations in medical gas field
once further studies are fulfilled and Xenon’s high cost is overcome.
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Medical gases have a wide scope of applications in med-
ical area. In the field of medicine, medical gases are used
for many practices such as anesthesiology, hyperbaric
oxygen therapy, neuroprotection and hypothermia [1].
For instance, hydrogen, the first element in periodic
table, is a medical gas that is synthesized in fermentation
of non-digestible carbohydrates in human cells [1-3], has
a neuroprotective role following middle cerebral artery
occlusion (MCAO) [4], neonatal HI [5,6] and newborn
pig asphyxia models [1,7]. Helium which has the second
highest prevalence in the universe [1] has therapeutic
effects on arrthymia [8] and inflammation [9,10], and
has myocardioprotective role [1,11]. Argon, another
noble gas has been used as anesthetic and neuroprotec-
tive agent [12]. Xenon which is a medical trace gas in
Earth’s atmosphere [13] is proven to be effective in the
fields of anesthesia and neuroprotection [12] (Figure 1).
In vitro and in vivo studies prove that Xenon has
therapeutic effects on various neurodegenerative out-
comes. Due to these promising results, in this paper we* Correspondence: johnzhang3910@yahoo.com
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reproduction in any medium, provided the oraimed to review the beneficial applications of Xenon in
clinical aspects mainly for neuroprotection as well as
anesthesia.Discovery and chemical properties of xenon
In 1898, Sir William Ramsay who was a Professor of
Chemistry at University College London discovered
Xenon. Ramsay, a Noble prizewinner for the discovery of
krypton and neon, also found Xenon with his student
Morris Travers in the residue of evaporating components
of liquid air [14,15]. Today, Xenon is still purified by frac-
tional distillation of liquefied air; similar to the method
Ramsay had performed [15]. With his findings, Ramsay
estimated that Xenon was found in 1 part in 20 million in
Earth’s atmosphere [14]. Recent studies prove the occur-
rence of Xenon that Ramsay had estimated [15].
After Xenon’s discovery in 1898, Albert R. Behnke Jr.
used different breathing mixtures including Xenon in his
studies of exploring the drunkenness in deep sea divers
[16]. He concluded that Xenon could be used as an anes-
thetizing agent with the results obtained from his trials in
1939. Following this outcome, Xenon was used as a surgi-
cal anesthetic agent for the first time by Stuart C. Cullen
and Gross in 1951 [16,17]. It was selected to be an effect-
ive anesthetic with its low blood-gas partition coefficientl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and






















Figure 1 Schema Summarizing Xenon’s applications: Noble gas xenon is used in various fields. In medicine, Xenon can be utilized as a
neuroprotective and anesthetic agent. It can also be used as a contrast agent in imaging. Plus it has the potential to be used in the field
of optics.
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ity to penetrate through blood brain barrier without ex-
tensive effort [14,17,18]. These advantageous properties
enable Xenon to have a rapid induction, which is a key
element in anesthesia [1,17]. Therefore, among the first
five noble gases in the periodic table that are helium,
neon, argon, krypton and Xenon, Xenon is the most
potent in anesthesia [20]. Moreover, Xenon is non-
teratogenic [14] and non-fetotoxic [15,21]. Hence, it is a
good interest for research with its possible neuroprotec-
tive and anesthetic properties.
Xenon is a colorless, heavy and odorless noble gas [1].
Having the chemical properties of noble gases, Xenon
cannot form covalent bonds with other molecules. How-
ever, it can still have binding action via van der Waals
forces. These forces occur in instantaneously polarized
atoms. This can be the only mechanism of binding, since
noble gases are non-polar and uncharged. Spontaneous
polarization enables the formation of a charged binding
site of the atom so that it can attract surrounding mole-
cules. In Xenon’s case, spontaneous polarization of
Xenon helps it bind the active sites of enzymes and
receptors by interfering with amino acids [12,22].
Thanks to its high number of electrons and lower-
binding energy, Xenon’s ability to be polarized is greatest
among other noble gases [12].Neuroprotective role of xenon
Cardiac arrest (CA) is one of the major causes of death in
both United States and Europe [23,24]. Although with
advanced and adventitious cardiopulmonary resuscitation
systems, almost 50% of CA victims are saved [25,26], the
next threat for resuscitated patients is global cerebral
hypoxia-ischemia [27,28]. It increases the mortality after
sudden CA with the mechanism of necrosis or apoptosis
of neuronal tissue [29-31]. Cognitive dysfunction, a per-
manent or transient inability to perform daily activities
[32,33] is an expected result, especially due to hippocam-
pal injury [34-36].
Another major risk group that is affected by hypoxia-
ischemia is neonates, because of the devastating na-
ture of labor procedure. Up to 1-2/1000 live births
result in severe hypoxia-ischemia and 60-70% of the
ones suffering from hypoxia-ischemia may die or
suffers life-long disabilities [37]. The risk of having
hypoxia-ischemia after CA or in perinatal period can-
not be anticipated but should be scrutinized. Since the
risk of having hypoxia-ischemia is unpredictable, it is
unlikely to develop a method to be administered prior
to insult [19]. Consequently, a therapeutic strategy or a
neuroprotective agent should be evolved to manage
and limit the effects of hypoxia-ischemia after it
eventuates [17].
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Recent in vivo studies on sub-anesthetic dosage of
Xenon with 50% concentration had promising results
against neonatal hypoxia-ischemia [1], CA induced cere-
bral ischemia [36] and neurobehavioral dysfunction
caused by brain insult [38]. Major mechanisms lying be-
hind Xenon’s neuroprotective property are the reduction
of ischemia-induced neurotransmitter release [39] as
well as the antagonistic property against NMDA recep-
tors [36,37,40] (Figure 2). It has been proven by Franks
and his colleagues that Xenon’s property of being antag-
onist to NMDA receptors is a key factor [41], since
NMDA receptors are primarily involved in initiation and
progression of apoptosis in neural tissue [19,42]. Fries
et al. state that after Xenon treatment, there was a re-
duction of perivascular inflammation in putamen and
caudate nucleus on pigs with post CA [36]. In addition,




Figure 2 Mechanism of Xenon’s neuroprotective action: The underlyin
effect is based on blockage of NMDA receptors. Without Xenon blocka
overstimulation of NMDA receptors leads to cell death by various pathway
site of NMDA receptors.of Xenon administration in neonatal rats which were
exposed to hypoxia-ischemia [1,43]. Also, it was demon-
strated that preconditioning of Xenon displays neuropro-
tective effects like reducing the size of infarction and
enhancing neurological functions in neonatal rats having
hypoxia-ischemia [1,44]. It has also been indicated that
Xenon has a higher efficacy in cortex rather than subcor-
tex due to the difference in vascularity and in density of
NMDA receptors in two distinct layers of cerebrum [45].
Another beneficial property of Xenon is its non-toxic
chemical characteristic which enables the usage of the
gas on neonates. The high risk of any traumatic event
during childbirth brings the idea of Xenon precondition-
ing to mother as a method of reducing the possibility of
brain insult to the neonate [46]. Xenon is an ideal gas
for this model with its cardiovascular stability [47] and
myocardial protection property [48], as well as its rapid
















g mechanism of action which Xenon exerts its neuroprotective
ge, increase in cytoplasmic calcium concentration due to
s. Xenon inhibits these cascades by competitively binding to glycine
Table 1 In-vivo and in-vitro models demonstrating the neuroprotective effects of Xenon
Reference Model Intervention Results
Bantel et al., 2009 Neuronal damage due to OGD Preconditioning with 75% Xenon for 2 hours Xenon preconditioning reduces neuronal injury through activation of
plasmalemmal ATP sensitive potassium channel [62]
Liu et al, 2011
Wilhelm et al, 2002
Neuronal damage due to OGD Xenon saturated medium for 24 hours (in vitro) Reduction in lactate dehydrogenase release proves that Xenon reduces OGD
induced neuronal cell death at subanesthetic concentrations [1,61].
Homi et al, 2003 MCAO in mice 70%, 35% Xenon during middle cerebral artery
occlusion for 1 hour
Application of Xenon during MCAO reduces total infarct size and augments
neurologic outcome [54].
Horiguchi et al, 2006 MCAO in mice Preconditioning with 70% xenon for 2 hours Xenon preconditioning induces neuroprotection in mice model of
middle cerebral artery occlusion [64].
Hobbs et al, 2008 Neonatal HI Hypothermia (32°C) with inhalation of
50% Xenon for 3 hours
Combination of hypothermia and Xenon increases neuroprotection from
37% (hypothermia only) to 76% [70].
Martin et al, 2007 Neonatal HI Asynchronous application of Xenon
(20%) and hypothermia (35°C) with 1 hour and
5 hours gap in between the treatments
Asynchronous combination of Xenon and hypothermia
reduces brain infarction significantly [71].
Ma et al, 2006
Luo et al, 2008
Neuronatal damage due to OGD Combination of 20% Xenon and
0.75% sevoflurane preconditioning
Combination of Xenon and sevoflurane preconditioning induces
long term neuroprotection by enhanced phosphorylated cyclic adenosine
monophosphate response element binding protection signaling. [53,55]
In oxygen glucose deprivation induced neuronal damage and middle cerebral artery occlusion in mice models, both Xenon preconditioning and its co-administration with insult grant neuroprotection. Combinations
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Xenon for neuroprotection was approved in Europe in
2007 [50,51].
Focal cerebral ischemia, in which a blood clot occludes
blood vessels of the brain [52], is commonly induced by
in-vivo animal model called filament occlusion of middle
cerebral artery [45]. It has been indicated that applica-
tion of Xenon during MCAO in mice reduces total in-
farct size and augments neurologic outcome [18,19,45].
Besides its co-administration with the injury, its precon-
ditioning also provides neuroprotection in mice model
of MCAO [53].
In-vitro studies
Oxygen glucose deprivation (OGD), which is one of
the in vitro models of ischemia, is a condition that
neurons undergo when cerebral blood flow is dis-
rupted. This deprivation activates excitoxicity in which
NMDA glutamate receptors are over stimulated, leading
to neuronal death through apoptosis and necrosis [18]. It
has been shown that Xenon reduces neuronal injury by its
administration before and during the insult [20,44,54].
Bantel et al. demonstrated neuronal preconditioning prop-
erty of Xenon by exposing neuronal-glial co-cultures
to 75% Xenon for 2 hours [55] as illustrated in Table 1.
Another study that was held by Maleeha et al. showed
that Xenon preconditioning protects human kidney
cells from OGD injury. They proposed the mechanism
in which survival factors p-Akt, HIF-1a and Bcl-2 are
upregulated [20].
Xenon also acts as a neuroprotectant when co-
administered with OGD injurious agents. It has been
shown that Xenon reduces OGD induced neuronal
cell death in mouse neuronal-glial cell co-culture at
subanesthetic concentrations. Since lactate dehydro-
genase release is an indication for cell injury, Xenon’s
mentioned neuroprotective role has been assessed by
the reduction in lactate dehydrogenase release [1,54].
Helene et al. also proved that Xenon reduces lactate
dehydrogenase and dopamine release, which is a key
event in excitotoxicity in OGD [18]. This again shows
that Xenon attenuates neuronal injury when it is co-
administered with OGD.
Combination therapy studies
Currently, hypothermia is the only intervention that pro-
vides neuroprotection after hypoxia-ischemia [37,56-58].
It has been proven that it enhances neurological outcome
after hypoxia-ischemia not only in neonatal rats, pigs, and
sheep but also in infants who suffer from hypoxic ische-
mic encephalopathy [14] and adults after out-of-hospital
CA [59]. Hypothermia makes it possible for one in six
infants with neonatal encephalopathy to have reduced
neurological deficits [58,59]. In order to increase this ratio,drugs which are able to enhance hypothermia’s neuropro-
tection should be investigated. Xenon is a promising can-
didate for this role because of its lack of chemical
reactivity, lack of side effects, non-fetotoxicity, and easy
reversibility [37].
Studies have shown that Xenon augments neuroprotec-
tion when combined with hypothermia in animal hypoxia-
ischemia models [43,60]. Hobbs et al. have demonstrated
that a combination therapy of hypothermia (32°C) with in-
halation of 50% Xenon for 3 hours increases neuroprotec-
tion from 37% (hypothermia only) to 76% (hypothermia
combined with xenon inhalation) [60,61]. The synergistic
neuroprotective effect of this treatment is still obtained
even after asynchronous administration of Xenon and
hypothermia. When Xenon (20%) and hypothermia (35°C)
were applied asynchronously with 1 hour and 5 hours gap
in between the treatments, their neuroprotective effect
combined synergistically and brain infarction in neonatal
rat hypoxia-ischemia model was reduced significantly [62].
Hypothermia decreases the release of glutamate that
binds to NMDA receptors. It also reduces the release of
glycine which assists glutamate to act on the NMDA
receptor. Since Xenon is a NMDA receptor antagonist,
hypothermia’s role of decreasing neurotransmitter and
Xenon’s role of receptor blockage converge on an anti-
apoptotic pathway [61]. This mechanism might also ex-
plain why asynchronous administration of Xenon and
hypothermia still improves the neurologic outcome of
hypoxia-ischemia [14].
It has also been studied whether a combination therapy
of Xenon with other drugs like dexmedetomidine and
sevoflurane is effective against hypoxia-ischemia. Combin-
ation of Xenon with dexmedetomidine reduces OGD
induced brain infarction in vivo [63]. Also, OGD injury is
decreased in vivo by independent preconditioning of
Xenon and sevoflurane [44,46]. Yan et al. have shown that
combination of Xenon and sevoflurane preconditioning
induces long term neuroprotection in neonatal asphyxia.
This combination gives the chance to apply Xenon in
lower doses, thus to decrease its high cost [46].
Mechanism of action
Xenon is an NMDA receptor antagonist [41]. It competi-
tively binds to the same site as NMDA receptor co-
agonist glycine [64] by interacting with the aromatic ring
of phenylalanine 758 [65]. Inhibition of NMDA receptors
by this binding enables Xenon to perform its anesthetic
and neuroprotective roles [41,64].
NMDA receptor is an ionotropic receptor that is acti-
vated by binding of glutamate [66]. Although glutamate is
the main excitatory neurotransmitter of central nervous
system, its excessive or constant activation of NMDA re-
ceptor causes neuronal death after ischemia or stroke due
to increase in cytoplasmic calcium concentration [66-70].
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increases the nitric oxide (NO) production and cell mem-
brane lipid peroxidation. NO, a free radical, is a potent
vasodilator and is synthesized by NO synthase in endothe-
lial cells and neurons in response to rise in intracellular
calcium. Excessive generation of NO causes mitochondrial
dysfunction. NO and superoxide (O2
–) react, resulting in
large amounts of peroxynitrite (ONOO-) generation.
Peroxynitrite causes DNA damage via oxidative reac-
tions [71]. Additionally, increased calcium concentra-
tion results in activation of calpain, which in turn
activates p38 (pro-death kinase), activation of stress-
induced protein kinase (such as p38 and JNKs) and ag-
gregation of proteins and nucleic acids that deteriorates
lipid bilayer membrane [72] resulting in cell death.
Xenon blocks NMDA receptor at the glycine binding
site [73] and inhibits these excitotoxic pathways, thus
establishes neuroprotection [74].
In addition, Xenon, like general anesthetics, is known to
produce hypothermic effect which is also neuroprotective
[74]. Hypothermia reduces excitotoxicity by decreasing
glutamate and glycine release [61] and interfering with
formation of reactive oxygen species [75].
Anesthesia
The use of modern anesthesia was introduced by Dr.
William Morton in 1846 [76] during a dental surgery
with inhalation of ether and the word ‘anesthesia’ was
introduced by Dr. Oliver Wendell Holmes in the same
year [77]. In general anesthesia, most preferred drugs
are volatile anesthetics which are structurally related to
ethers. These molecules are relatively more soluble in
lipids than in water, so it is believed that their primary
site of action is membrane proteins of nerve cells [78].
Recently there has been a renewed interest in one of
the noble gases, Xenon, because of its cardio protective
profile. On controversy to halogenated ethers, Xenon
anesthesia has no harm on cardiovascular system fur-
thermore it has a neuroprotective effect [79]. Yet there
is still limitation in its widespread application due to its
highly costs.
Although Xenon was declared to be a possible anes-
thetizing agent in 1939 by Albert R. Behnke Jr, it took 7
more years to be proven that Xenon has anesthetic
properties by the publication of John H. Lawrence [80].
Five years had passed after the first publication to be
used in a human surgery that was accomplished by
American anesthesiologists Stuart C. Cullen in 1951
[45,80]. Till 1990s, Xenon was not a gas which was in-
tensively researched on [81]. However, in last decades
the popularity of Xenon increased due to its harmless
and beneficial profile. Russia was the first country to ap-
prove the application of Xenon in anesthesia in 2000.
Germany was the next country to authorize in 2005. In2007, the approval for the usage of Xenon as an
anesthetic agent was extended to all Europe [80,82].
Xenon is claimed to be an ideal anesthetic due to its
unique properties [19,81,82]. It was observed that patients
receiving Xenon anesthesia have a shorter recovery time
and reduced post-operative pain [81] when compared to
patients exposed to other volatile anesthetics [19]. The
reason underneath is Xenon’s low blood-gas partition co-
efficient [83].
It was also proven that Xenon doesn’t have any side
effects to human body [81,84,85]. It has been shown
in vitro that Xenon doesn’t cause any coagulation [86] or
platelet dysfunction [87] and it doesn’t deteriorate hepatic
or renal functions [88,89]. Besides its organoprotective
property, it demonstrates a low blood-gas partition coeffi-
cient of 0.115 and fast diffusion rate through blood brain
barrier which enables Xenon to be both inducted and
washed out in a short amount of time [13]. Xenon has fur-
ther advantages like preferred hemodynamic stability [80]
and rapid perfusion to specific organs [16]. As a result,
Xenon is correlated with maintaining a slower heart rate
and a greater arterial pressure value than other anesthetics
[90]. This adventitious cardiovascular profile enables the
usage of Xenon as an anesthetic agent during the opera-
tions on patients having coronary artery disease with
tachycardia and low arterial pressure that are life threaten-
ing for them [91].
Other than being non-hazardous to cardiovascular sys-
tem, Xenon can be also used as an anesthetic agent be-
cause of its additional neuroprotective role [41,92]. Most
general anesthetics induce anesthesia by potentiation of
gamma-amino butyric acid receptor which is an inhibitory
synaptic receptor [77]. Xenon, on the other hand performs
its anesthetic role by blocking NMDA receptor similar to
its neuroprotective mechanism [1,41]. This blockage inhi-
bits excitatory neurotransmission of NMDA receptors,
thus causes anesthesia. Franks et al. proved that 80%
Xenon decreased NMDA-activated currents by appro-
ximately 60%. Xenon’s blockage of NMDA receptors
enables it to have anesthetic effects, since NMDA recep-
tors are involved in synaptic mechanisms of perception of
pain, learning and memory [41]. It is claimed that Xenon
induces anesthesia also by activating two pore domain
background potassium channel TREK-1 [19]. Once acti-
vated, these channels cause neuronal hyperpolariza-
tion. Consequently, cellular excitability is decreased
and anesthesia is provided [93,94].
Besides NMDA receptor, the other two glutamate recep-
tors are α-amino-3-hydroxy-5-methyl-4-isoxazolole propi-
onate (AMPA) receptor and kainate receptor which are
also called as “non-NMDA receptors”. Since the structures
of these three glutamate receptors are very similar to each
other, whether AMPA and kainate receptors are additional
molecular targets for Xenon has been investigated [39].
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inhibiting NMDA receptors, whereas the studies on its
effects on AMPA and kainate receptors are contradictory
[95]. In a study performed by Plested et al., AMPA recep-
tor was expressed in Xenopus oocytes and HEK-293 cells.
Its sensitivity to Xenon and how it was affected by
desensitization was observed by bath application of Xenon
and the recording of the resulting ionic currents. When
kainate was used as an artificial agonist, Xenon blocked
AMPA receptor due to desensitizing response elicited by
kainate. In the second part of the study, glutamate which
is a natural agonist of AMPA receptor was used rather
than kainate by an ultra-rapid application system which
mimicked the rapid release of high-concentration glutam-
ate at synapses. This time Xenon didn’t block AMPA
receptor due to lack of desensitization. Therefore, it was
concluded that the sensitivity of AMPA receptor to Xenon
depended on desensitization and that AMPA receptor was
not blocked during anesthesia with Xenon [96].
Dinse et al., on the other hand, demonstrated by using
voltage-clamped cortical neurons from embryonic mice
that desensitization still occurred with the fast application
of glutamate. Xenon blocked AMPA and kainate receptors
even when glutamate was used as the agonist, so it was
concluded that the blockage of AMPA and kainate recep-
tors in cortical neurons contributed to Xenon’s anesthetic
property [39]. Georgiev et al. agreed that Xenon per-
formed its anesthetic action by blocking both NMDA and
AMPA receptors but they claimed that this blockage
occurred in spinal cord dorsal horn neurons rather than
cortical neurons [95]. When these contradictory studies
are examined, it is seen that the role of AMPA and kainate
receptors in Xenon’s anesthetic action is not as clear as
the role of NMDA receptor [39]. Therefore, further inves-
tigations are needed for enriching Xenon’s anesthetic
mechanisms.
Use of xenon in optics
In the field of optics, noble gas Xenon is used for vari-
ous purposes. After its discovery, Xenon was used in
flash lamps for the first time for photography [97].
Today the majority of cameras still use Xenon gas in
modern flash technology. Many of the gas-discharge
lamps that we use in our daily lives like car bulbs and
ceiling lights contain Xenon for energy-efficient illumin-
ation as well.
Xenon compounds are also used commonly in modern
laser technology. Excimer lasers that are used for photo-
lithography and laser eye surgery contain Xenon gas
[98]. Under appropriate conditions of high pressure and
electrical stimuli, Xenon gives rise to laser light in ultra-
violet range by forming a compound with other excitable
molecules. This relatively cheap but easy method makes
it possible to selectively remove micrometer size filmsfor producing computer chips and provide treatment to
people who suffer from myopia, hyperopia and astigma-
tism [99].
Since Xenon flash lamps have an emission spectrum
ranging from ultraviolet to infrared light, these lamps are
also used in food industry and dermatological practices. In
food industry, Xenon flash lamps are designed in a way
that they provide high power pulses of light for killing
microorganisms including bacteria, yeasts, molds and
viruses [100-102]. This treatment is approved by Food and
Drug Administration (FDA) in United States since it is an
effective thermal treatment for food decontamination. In
dermatologic practices, intense pulsed light is used for re-
moval of hair and photo-rejuvenation [103]. Once applied
to skin, light beams at a specific wavelength will target
bulbs of hair where melanin pigments are abundant. The
heat generated by the absorbed light will vaporize hair
bulbs, which will lead to hair reduction in skin. The
same principle also applies for removal of skin lesions.
By using specific wavelengths and intensity of light,
photo-rejuvenation therapies can remove pigmented
lesions [104]. This is achieved by harnessing the effi-
cacy of monochromatic excimer light [105].
Medical imaging
With the last technological advancements in nuclear
medicine; different methods were developed in recent
years aiming for better results. The idea of using Xenon
gas was introduced lately in computed tomography (CT)
- imaging as well as single-photon emission computed
tomography (SPECT) since it has some advantages over
other techniques that are currently being used [106].
Xenon enhanced CT scanning is an easy and non-
invasive method in which patients inhale the stable
(131Xe) gas while CT images are made. It can be used for
various findings like measuring cerebral blood flow after
a traumatic brain injury. When clinical urgency of a trau-
matic patient is considered, Xenon enhanced CT is a fast
and reliable procedure since less than 15 minutes of gas
inhalation is required for the process. In this method,
non-radioactive molecule Xenon (131Xe) is used as a con-
trast agent [107], for getting good resolution images
[108]. It is non- hazardous for the body since half-life of
131Xenon is about 40 seconds in cerebral tissue so it is
washed away rapidly after inhalation [109]. Once inhaled,
diffusion rate of the gas into tissue would indicate the
amount of blood flow that area is receiving, so that fur-
ther clinical examinations can be administered. This
technique is also used for measuring tissue blood flow in
pancreatic tumors [110].
In SPECT, radioactive isotope (133Xe) of Xenon is
used as radionuclide. Since Xenon is a small inert mol-
ecule, soluble in lipid and water, readily exchanged be-
tween blood and tissue, and diffusible in the brain, it is
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nique can be used for obtaining quantitative and repeat-
able whole-brain scans [111], ventilation studies of
lungs, measurement of cerebral blood flow [107] to
study pathology of dementia, Alzheimer's disease, epi-
lepsy, obsessive-compulsive disorders [112].
Toxicity
Volatile and inhalation anesthetics are dangerous for
ozone layer because of their chlorofluorocarbon based
structures [19]. One of the inhalational agents, nitrous
oxide, is 230 times more potent as a greenhouse gas
when compared with carbon dioxide [113]. On contrary,
Xenon has no undesirable ecological effects since it is a
naturally occurring gas in Earth’s atmosphere.
Xenon is a good candidate for being an ideal anesthetic
not only because of its beneficial effects, but also its lack
of toxicity. Besides being non-neurotoxic, Xenon doesn’t
have any effect on hematological and biochemical vari-
ables as well [88]. It has been shown that Xenon has no
impact on coagulation/platelet function [87], nor on im-
mune system [114]. Xenon is non-reactive in the body, it
is disposed from the lungs without interfering with hepatic
and renal systems, thus it doesn’t impair hepatic or renal
function [88,89].
Cost-efficiency
Xenon is a trace element in Earth’s atmosphere [60], ex-
pense of its fractional distillation is very high and it cannot
be industrially synthesized [50]. Therefore, Xenon is rela-
tively more expensive than other anesthetic and neuropro-
tective agents [115]. Xenon’s scarcity and high cost (10
$/L) [85] are major handicaps along the way of being used
commonly as an ideal anesthetic and neuroprotectant
[60]. While other volatile anesthetics have a cost around
10$ for 2 hours of administration, Xenon’s expense for the
same time interval is 300$ in total [90]. Consequently,
cheaper methods should be investigated to use Xenon
more efficiently and economically. A closed-circulatory
system is recently developed for this scope [18], enabling
the reuse of Xenon gas and mechanical replenishment of
oxygen [61]. On the other hand, the high cost of Xenon
might not be as great as it seems, since Xenon anesthesia
improves clinical outcome. Reduced hospital stay duration
and decreased need of post-operative intensive care might
outweigh the cost of Xenon [90]. It seems further studies
are necessary to evaluate cost effectiveness of Xenon in
clinical usage.
Conclusion and further studies
Xenon has a bright future in medicine due to its notice-
able advantages over other anesthetic agents. Despite
of its highly costs, its neuro and myocardio protective
profile, non-toxic chemical properties, nature friendlyfeature and efficacy in hypoxia-ischemia treatment com-
bined with hypothermia makes it an ideal candidate for
innovations in medical gas field. Promising findings
obtained from in vivo-vitro studies of xenon denote that
xenon will take its part in neuroprotective treatments
for brain trauma, resuscitation and ischemic insults.
However, further research and large-scale investigations
are necessary for utilizing Xenon’s therapeutic potential
maximally. The highly cost of Xenon should also be
overcome for achieving this goal.
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